Key Highlights

  • The stock was up 8.80% to USD 2.35 in pre-market trading on November 3, 2026.
  • No company announcement dated October 30 to November 3, 2026 was identified as the trigger.
  • The PLATEAU Phase 2b trial is fully enrolled with 239 patients.
  • Cash, cash equivalents and restricted cash were USD 23.9 million as of June 30, 2026.
  • Fiscal third quarter net loss was USD 7.0 million, or USD 0.30 per share.

What moved Veru shares in pre-market trading (up USD 0.1901, 8.80%)?

Veru (NASDAQ:VERU) was up 8.80% to USD 2.35 in pre-market trading on November 3, 2026.

No company press release or regulatory filing dated between October 30 and November 3, 2026 was identified. The most recent company update found was dated September 8, 2026, so the move may reflect momentum or sector sentiment around obesity drug developers rather than new company news.

What is Veru working on?

Veru is a clinical stage biopharmaceutical company. Its lead program is enobosarm, an oral selective androgen receptor modulator that the company positions as a way to preserve lean mass and physical function during GLP-1 weight loss.

The Phase 2b PLATEAU trial tests enobosarm 3 mg with semaglutide in adults aged 65 and older with obesity and a body mass index of at least 35. According to a company press release dated August 10, 2026, enrollment reached 239 patients against a target of 200.

What did the latest results and updates say?

For the quarter ended June 30, 2026, the company reported a net loss of USD 7.0 million, compared with USD 7.3 million a year earlier.

The company said an interim analysis of lean and fat mass at 32 weeks is expected in the first quarter of calendar 2027, with final topline data in the fourth quarter of 2027. It also reported a June 2026 clinical Supply agreement with Novo Nordisk (NYSE:NVO) that can be ended on 60 days' notice, and a notice of allowance for a U.S. Patent covering enobosarm with weight loss drugs.

What are the Balance Sheet and risk considerations?

Cash, cash equivalents and restricted cash were USD 23.9 million at June 30, 2026, up from USD 15.8 million at September 30, 2025. Nine month net cash used in operations was USD 20.6 million, so the company will likely need additional Capital before final PLATEAU data arrive, which could mean dilution.

On September 8, 2026, the company said it plans a Phase 2b trial of sabizabulin in metastatic pancreatic cancer after prior treatment with daraxonrasib, and would seek FDA feedback in the fourth quarter of 2026. It also said it would stop developing sabizabulin for atherosclerotic cardiovascular inflammation. This is a penny stock, so illiquidity and sharp swings are possible.

What should investors watch next?

The first item is any report of FDA feedback on the pancreatic cancer plan, which the company guided to the fourth quarter of 2026.

Further PLATEAU updates ahead of the first quarter 2027 interim analysis, and any financing announcement, are the other markers to follow.